Positron sells four Attrius PET scanners

Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, announces the sales of four Attrius™ PET scanners to prominent cardiology practices and orders six Attrius™ PET scanners from its joint venture, Neusoft Positron Medical Systems for immediate delivery.

As a result of the Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule whereby reimbursement for cardiac PET increased and reimbursement for SPECT decreased there has been a significant increase in demand for cardiac PET imaging. When combining the economic and medical imaging advantages of cardiac PET compounded with the continued shortage of Molybdenum, the parent radioisotope used in SPECT imaging, this increase in the demand for cardiac PET is a trend that is expected to continue.

Positron's cardiac optimized dedicated PET scanner the Attrius™ is the right choice at the right time for cardiovascular practices. With recent sales, Positron has met its six month projections and predicts greater demand moving forward. Based on Positron's sales pipeline and in preparation of meeting the next six month projections, the Company has place a purchase order for six systems for their earliest delivery. Positron's organic growth targets sales of 17 PET systems for 2010, 50 PET systems for 2011 and 125 PET systems for 2012 and fully expects to meet these goals.

Patrick G. Rooney, Chief Executive Officer of Positron stated, "Positron has always been a leader in cardiac PET and we continue to make progress that further validates our position that PET is the future of nuclear cardiology. Positron is ideally positioned with the Attrius™ as the only dedicated cardiac PET offering available. This year has seen the emergence of cardiac PET and Positron. Our objective is to meet the strong demand and be the full solutions provider for cardiac PET adopters. Positron projects an increase in sales every quarter for the foreseeable future and is prepared to deliver. Positron's corporate focus is aggressive growth while staying on track to deliver positive earnings within 18 months."